Baqsimi nasal powder ( glucagon), first treatment for severe hypoglycemia that can be administered without an injection
The U.S. Food and Drug Administration has approved Baqsimi nasal powder, the…
Vitrakvi (larotrectinib), first ‘histology-independent’ treatment for solid tumours with a specific gene mutation
EMA’s human medicines committee has recommended granting a marketing…
Victoza, liraglutide, new treatment for children with type 2 diabetes
EMA’s human medicines committee has recommended granting an extension of…
Dupixent (dupilumab), first treatment for chronic rhinosinusitis with nasal polyps
The U.S. Food and Drug Administration has approved Dupixent (dupilumab) to…
FDA approves Soliris (eculizumab), first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system
The U.S. Food and Drug Administration has approved Soliris (eculizumab)…
FDA approves Xpovio (selinexor), new treatment for refractory multiple myeloma
The FDA has granted accelerated approval to Xpovio (selinexor) tablets in…
Piqray (alpelisib), first PI3K inhibitor for breast cancer
The U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to…
Zolgensma (onasemnogene abeparvovec-xioi), innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality
The U.S. Food and Drug Administration has approved Zolgensma (onasemnogene…
FDA approves Fragmin (dalteparin sodium) first anticoagulant for pediatric patients to treat potentially life-threatening blood clots
The U.S. Food and Drug Administration has approved Fragmin (dalteparin sodium)…
Dengvaxia, the first vaccine approved by FDA for the prevention of dengue disease caused by all dengue virus serotypes
The U.S. Food and Drug Administration has announced the approval of Dengvaxia,…